Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abandoned AstraZeneca Compounds “Given” To U.K. R&D Academics

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca is giving 15 shelved compounds to U.K.-based academics in a collaboration funded by public money that may produce scientific breakthroughs along with thorny IP issues.

Advertisement

Related Content

U.K Drug-Repurposing Program Expands, Attracts Industry Support
Seeing Is Believing: GSK Pledges To Upgrade Key Antibiotics Plant As Witty Hosts Q3 Call From Singapore
NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative
AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction
AstraZeneca Collaboration With Medical Research Council May Mean New Life For 22 Compounds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel